Ashley Dreier - HealthEquity Executive Vice President CTO and CIO
| HQY Stock | USD 78.55 1.20 1.50% |
President
Ms. Ashley Dreier is Executive Vice President, Chief Technology Officer and Chief Information Officer of the Company. Ms. Dreier has served as our Executive Vice President, Chief Technology Officer and Chief Information Officer since February 2013. Ms. Dreier is responsible for leading our technical and product development teams and ensuring strategic alignment and execution of our platform strategy. From May 2008 to February 2013, Ms. Dreier was Vice President of Product Development and Technology at Krames StayWell, a provider of interactive, print and mobile patient education solutions, consumer health information and population health management communications in the United States. Prior to joining Krames StayWell, Ms. Dreier was the Director of Product Development at GE Capital, where she was responsible for development of software products associated with corporate purchasing and travel and entertainment credit cards since 2013.
| Age | 44 |
| Tenure | 11 years |
| Address | 15 West Scenic Pointe Drive, Draper, UT, United States, 84020 |
| Phone | 801 727 1000 |
| Web | https://www.healthequity.com |
HealthEquity Management Efficiency
The company has Return on Asset of 0.0256 % which means that on every $100 spent on assets, it made $0.0256 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0284 %, implying that it generated $0.0284 on every 100 dollars invested. HealthEquity's management efficiency ratios could be used to measure how well HealthEquity manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.07 in 2024, whereas Return On Capital Employed is likely to drop 0.04 in 2024. At this time, HealthEquity's Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 51 M in 2024, whereas Other Assets are likely to drop 0.95 in 2024.Similar Executives
| Found 12 records | PRESIDENT Age | ||
| Mike Martin | Northrim BanCorp | N/A | |
| Larry Kirsch | PC Connection | N/A | |
| William Schulze | PC Connection | 55 | |
| Edwin Moran | Omega Flex | 56 | |
| Michael Huston | Northrim BanCorp | 56 | |
| Thomas Baker | PC Connection | 59 | |
| Joseph Driscoll | PC Connection | 49 | |
| Stephen Sarno | PC Connection | 50 | |
| Michael Martin | Northrim BanCorp | 50 | |
| Jed Ballard | Northrim BanCorp | 39 | |
| Benjamin Craig | Northrim BanCorp | 49 | |
| Rick Gilligan | PC Connection | N/A | |
Management Performance
| Return On Equity | 0.0284 | ||||
| Return On Asset | 0.0256 |
HealthEquity Leadership Team
Elected by the shareholders, the HealthEquity's board of directors comprises two types of representatives: HealthEquity inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HealthEquity. The board's role is to monitor HealthEquity's management team and ensure that shareholders' interests are well served. HealthEquity's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, HealthEquity's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthew Sydney, Executive VP of Sales and Marketing | ||
| Frode Jensen, Executive Vice President - General council and secretery | ||
| Robert Selander, Non-Executive Chairman of the Board | ||
| Evelyn Dilsaver, Independent Director | ||
| Edward Bloomberg, COO, Executive Vice President | ||
| Adrian Dillon, Director | ||
| William Otten, Executive Vice President of Sales | ||
| Larry Trittschuh, Executive Vice President Chief Security Officer | ||
| Jon Kessler, CEO and President and Director | ||
| Stephen Neeleman, Vice Chairman of the Board, Founder | ||
| Delano Ladd, Executive Vice President General Counsel and Corporate Secretary | ||
| Jon Soldan, Executive VP of Operations | ||
| Debra McCowan, Director | ||
| Frank Corvino, Independent Director | ||
| Manu Rana, Independent Director | ||
| Gary Robinson, Executive Vice President Chief Marketing Officer | ||
| Elimelech Rosner, Executive CTO | ||
| Tia Padia, Executive Officer | ||
| Richard Putnam, IR Contact Officer | ||
| James Lucania, CFO VP | ||
| Ian Sacks, Independent Director | ||
| Angelique Hill, Executive Vice President - Operations | ||
| Michael Leavitt, Independent Director | ||
| Darcy Mott, CFO, Executive VP and Treasurer | ||
| Gayle Wellborn, Director | ||
| Brad Bennion, Senior Development | ||
| Tyson Murdock, Ex CFO | ||
| Jonathan Soldan, Executive Vice President - Operations | ||
| Steve Lindsay, Executive Management | ||
| Frank Medici, Independent Director | ||
| Ashley Dreier, Executive Vice President CTO and CIO |
HealthEquity Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is HealthEquity a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0284 | ||||
| Return On Asset | 0.0256 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 7.4 B | ||||
| Shares Outstanding | 86.16 M | ||||
| Shares Owned By Insiders | 2.20 % | ||||
| Shares Owned By Institutions | 97.80 % | ||||
| Number Of Shares Shorted | 3.02 M | ||||
| Price To Earning | 525.29 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HealthEquity. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index. For more information on how to buy HealthEquity Stock please use our How to Invest in HealthEquity guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for HealthEquity Stock analysis
When running HealthEquity's price analysis, check to measure HealthEquity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HealthEquity is operating at the current time. Most of HealthEquity's value examination focuses on studying past and present price action to predict the probability of HealthEquity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HealthEquity's price. Additionally, you may evaluate how the addition of HealthEquity to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Stocks Directory Find actively traded stocks across global markets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is HealthEquity's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HealthEquity. If investors know HealthEquity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HealthEquity listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.96) | Earnings Share 0.64 | Revenue Per Share 11.682 | Quarterly Revenue Growth 0.122 | Return On Assets 0.0256 |
The market value of HealthEquity is measured differently than its book value, which is the value of HealthEquity that is recorded on the company's balance sheet. Investors also form their own opinion of HealthEquity's value that differs from its market value or its book value, called intrinsic value, which is HealthEquity's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HealthEquity's market value can be influenced by many factors that don't directly affect HealthEquity's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between HealthEquity's value and its price as these two are different measures arrived at by different means. Investors typically determine if HealthEquity is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HealthEquity's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.